Cinryze

Type: Product
Name: Cinryze
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

Lialda to save Shire's Q1 results

Q1’14 preview: expect revenues in line thanks to Lialda and 5% EPS beat Shire is to report Q1’14 results on May 1st 2014 at noon UK time and we expect US$1,389m in revenues (0.5% higher than Shire collected consensus), US$536m in non-GAAP EBIT (2.4% below ... [Published Invezz - Apr 17 2014]
Entities: LIALDA, Shire plc, Cinryze
First reported Apr 13 2014 - Updated Apr 13 2014 - 1 reports

Cost of Gilead's hepatitis C pill, Sovaldi, spurs revolt

The nation may have finally met a drug it cannot afford.Sovaldi is a long-awaited breakthrough for the 3 million Americans suffering from the hepatitis C virus. And at $1,000 a daily pill, or $84,000 over 12 weeks of treatment, the medication could generate ... [Published San Francisco Chronicle - Apr 13 2014]
First reported Apr 07 2014 - Updated Apr 07 2014 - 1 reports

FDA News Lifts Dyax Slightly

Shares of Dyax Corp. ( DYAX ) were up slightly to close the trading session on April 4 at $8.64 per share following the U.S. Food and Drug Administration’s (:FDA) decision to approve the company’s subcutaneous treatment KALBITOR (ecallantide) for a wider ... [Published Yahoo! Finance - Apr 07 2014]
First reported Apr 04 2014 - Updated Apr 05 2014 - 1 reports

UPDATE 2-Halozyme halts trial of drug delivery system, shares slump

(Adds background, analyst comment; updates shares)April 4 (Reuters) - Halozyme Therapeutics Inc halted a mid-stage trial testing an advanced version of its flagship drug delivery technology in patients with pancreatic cancer, sending its shares tumbling ... [Published CNBC - Apr 04 2014]
First reported Mar 26 2014 - Updated Mar 26 2014 - 1 reports

Will Shire PLC Build Or Buy Its Future?

The ideal in the biotech and pharma world may be for a company to develop a strong internal R&D engine that regularly churns out potential blockbuster compounds, but the reality is that most companies have to turn to partnerships and acquisitions to manage ... [Published Motley Fool Discussion Boards - Mar 26 2014]
First reported Mar 25 2014 - Updated Mar 25 2014 - 1 reports

NPS Pharmaceuticals Expands Executive Leadership Team to Support its U.S. and International Growth and Global Orphan-Drug Leadership

– Paul Firuta named President, U.S. Commercial Operations –Related Biotechnology, Pharmaceutical and Healthcare News-- Eric Pauwels promoted to President, NPS Pharma International --NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a global biopharmaceutical company ... [Published BioPortfolio - Mar 25 2014]
First reported Mar 16 2014 - Updated Mar 16 2014 - 1 reports

MEDICAL JOURNEY: Living through the pain | Video

Photo by Justin Zamudiophotos by Justin Zamudio/San Angelo Standard-Times Amanda Ojeda, a nurse at Shannon Medical Center, checks Britani Rodriguez’s blood pressure before administering a protein infusion last month at the Shannon Women’s and Children’s ... [Published San Angelo Standard-Times - Mar 16 2014]
First reported Mar 12 2014 - Updated Mar 13 2014 - 1 reports

Can Alexion Pharmaceuticals Continue to Deliver?

Successful biotechs are generally expected to reinvest their profits into the development of broad pipelines, but  Alexion   ( NASDAQ: ALXN     )  is following a somewhat different path. While I do not mean to give short shrift to this company's pipeline ... [Published Motley Fool Discussion Boards - Mar 12 2014]
First reported Feb 20 2014 - Updated Feb 20 2014 - 1 reports

Rarefied Air of Rare Disease Drug Pricing

BioMarin has set the price for its newly approved drug Vimizim, a treatment for Moquito A syndrome, at $380,000 per year. At that price, it expects to garner about $500 M in annual sales and the drug clocks in with the 3rd highest overall drug price. ... [Published The Big Red Biotech Blog - Feb 20 2014]
First reported Jan 27 2014 - Updated Jan 27 2014 - 1 reports

Is This Analyst Wrong About Halozyme?

Every once in a while, there is an event that makes investors scratch their heads. While most investors don’t base their investing decisions solely off sell-side upgrades/downgrades, it is still interesting to read them in order to perhaps gain ... [Published Wall St. Cheat Sheet - Jan 27 2014]
First reported Nov 11 2013 - Updated Nov 12 2013 - 3 reports

Shire buys ViroPharma for $4.2B

Shire Pharmaceuticals said Monday it is buying Exton area-based ViroPharma Inc. for $4.2 billion.The boards of both companies unanimously agreed on the transaction in which Shire will acquire all of ViroPharma’s outstanding shares for $50 each in cash, ... [Published Main Line Life - Nov 12 2013]
First reported Nov 11 2013 - Updated Nov 11 2013 - 1 reports

Nov. 11 Premarket Briefing: 10 Things You Should Know

NEW YORK (TheStreet) -- Here are 10 things you should know for Monday, Nov. 11 1.-- U.S. stock futures were signaling a flat start to Wall Street on Monday following Friday's report of strong jobs growth in the U.S.European stocks were rising slightly. ... [Published The Street Latest - Nov 11 2013]

Quotes

"People do wonder, is this a sea change?" Divan, the Credit Suisse analyst, said. "Is there going to be a lot more pressure on pricing in the U S ?"
"We joke around. They don’t make me focus on my problems." © 2014 San Angelo Standard Times. All rights reserved. This material may not be published, broadcast, rewritten or redistributed

More Content

All (19) | News (17) | Reports (0) | Blogs (2) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Lialda to save Shire's Q1 results [Published Invezz - Apr 17 2014]
Cost of Gilead's hepatitis C pill, Sovaldi, spu... [Published San Francisco Chronicle - Apr 13 2014]
FDA News Lifts Dyax Slightly [Published Yahoo! Finance - Apr 07 2014]
UPDATE 2-Halozyme halts trial of drug delivery ... [Published CNBC - Apr 04 2014]
Will Shire PLC Build Or Buy Its Future? [Published Motley Fool Discussion Boards - Mar 26 2014]
NPS Pharmaceuticals Expands Executive Leadershi... [Published BioPortfolio - Mar 25 2014]
MEDICAL JOURNEY: Living through the pain | Video [Published San Angelo Standard-Times - Mar 16 2014]
Can Alexion Pharmaceuticals Continue to Deliver? [Published Motley Fool Discussion Boards - Mar 12 2014]
Rarefied Air of Rare Disease Drug Pricing [Published The Big Red Biotech Blog - Feb 20 2014]
Is This Analyst Wrong About Halozyme? [Published Wall St. Cheat Sheet - Jan 27 2014]
Shire buys ViroPharma for $4.2B [Published Main Line Life - Nov 17 2013]
Business briefs: Late-payment rate on mortgages... [Published Spokesman-Review.com - Nov 12 2013]
Shire buys ViroPharma for $4.2B [Published Main Line Life - Nov 12 2013]
Dow Touches a Record Closing High in Light Session [Published Schaeffers Research - Nov 11 2013]
UPDATE - FTSE 100’s gains frustrated by BskyB a... [Published Proactiveinvestors United Kingdom RSS feed - Nov 11 2013]
Shire Buying Viropharma for $4.2B to Bolster Ra... [Published The Street Latest - Nov 11 2013]
The Deal: Shire to Spend $4.2 Billion on ViroPh... [Published The Street Latest - Nov 11 2013]
Nov. 11 Premarket Briefing: 10 Things You Shoul... [Published The Street Latest - Nov 11 2013]
ViroPharma to discontinue Phase II study of Cin... [Published Pharmaceutical Business Review - Aug 05 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Rarefied Air of Rare Disease Drug Pricing [Published The Big Red Biotech Blog - Feb 20 2014]
BioMarin has set the price for its newly approved drug Vimizim, a treatment for Moquito A syndrome, at $380,000 per year. At that price, it expects to garner about $500 M in annual sales and the drug clocks in with the 3rd highest overall drug price. ...
Is This Analyst Wrong About Halozyme? [Published Wall St. Cheat Sheet - Jan 27 2014]
Every once in a while, there is an event that makes investors scratch their heads. While most investors don’t base their investing decisions solely off sell-side upgrades/downgrades, it is still interesting to read them in order to perhaps gain ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.